http://www.prometic.com () —
ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI) will host its
Annual Meeting of Shareholders ("AGM") on Wednesday, May 18, 2024 at
10:30 a.m. (EDT) in Salon 3, Level 2 of the Centre Sheraton Montreal
Hotel, located at 1201 Rene-Levesque Blvd. West, Montreal.
The AGM will be followed by a corporate presentation which will
highlight the progress made with respect to ProMetic's small molecule
therapeutics program and regarding its plasma derived therapeutics
business; namely with respect to Wuhan Institute of Biologic Products
/ China National Biotech Group. Details regarding Prometic's new
plasma protein manufacturing facility and its impact on future growth
for the Company will also be discussed. Shareholders will receive an
update regarding ProMetic's prion removal technology / PCapt@ filter
adoption. The UK government released minutes regarding parliamentary
discussions held with respect to implementing precautionary measures
(including PCapt@ filter) to avoid prion infection / vCJD. To read the
full text, go to:
http://services.parliament.uk/hansard/Commons/bydate/20110428/mainchamberdebates/part007.html
(http://services.parliament.uk/hansard/Commons/bydate/20110428/mainchamberdebates/part007.html)
.
For those who are unable to attend in person, the Company will offer a
live audio conference call and web cast through ProMetic's website on
the Events page - http://www.prometic.com/en/news-events/events.php
(http://www.prometic.com/en/news-events/events.php) and in the
Highlights section of the Home page -
http://www.prometic.com/en/index.php. The numbers to access the
conference call are (416) 981-9000 (international) and 1 (800)
742-6164 (North America toll free).
An audio replay of the call will be available for a period of seven
days as of Wednesday, May 18, 2024 at 15:00 (EDT). The numbers to
access the audio replay are (416) 626-4100 (international) and 1 (800)
558-5253 (North America toll free) using access code 21517828. The
replay of the web cast may be downloaded directly from ProMetic's web
site.
In accordance with the provisions of section 14.3 of National
Instrument 51-102 Continuous Disclosure Requirements, the Company will
be taking the offered transitional 30-day filing extension for its
March 31, 2024 interim report, on the basis that it is disclosing, for
the first time, a statement of compliance with International
Accounting Standard 34 Interim Financial Reporting. As a result the
Company intends to file its first quarter report on June 14, 2011.
We are also pleased to announce that Mr. Frederic Dumais will be
joining ProMetic Life Sciences on May 9, 2024 as Director,
Communications and Investor Relations (IR). Mr. Dumais is a seasoned
IR professional with several years of experience in the
telecommunication and biotechnology industries. Mr. Dumais replaces
Ms. Anne Leduc. Mr. Dumais contact information as of May 9, 2024 shall
be: Tel: 1+ 450-781-0115, extension 2234; E-mail:
f.dumais@prometic.com (mailto:f.dumais@prometic.com) .
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com
(http://www.prometic.com) ) is a biopharmaceutical company specialized
in the research, development, manufacture and marketing of a variety
of commercial applications derived from its proprietary Mimetic
Ligand technology. This technology is used in large-scale
purification of biologics and the elimination of pathogens. ProMetic
is also active in therapeutic drug development with the mission to
bring to market effective, innovative, lower cost, less toxic products
for the treatment of hematology and cancer. Its drug discovery
platform is focused on replacing complex, expensive proteins with
synthetic "drug-like" protein mimetics. Headquartered in Montreal
(Canada), ProMetic has R&D facilities in the UK, the US and Canada,
manufacturing facilities in the UK and business development activities
in the US, Europe, Asia and in the Middle-East.